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Abstract
We conducted an association study across the human leukocyte antigen (HLA) complex to identify loci associated with
multiple sclerosis (MS). Comparing 1927 SNPs in 1618 MS cases and 3413 controls of European ancestry, we identified seven
SNPs that were independently associated with MS conditional on the others (each Pƒ4|10{6). All associations were
significant in an independent replication cohort of 2212 cases and 2251 controls (Pƒ0:001) and were highly significant in
the combined dataset (Pƒ6|10{8). The associated SNPs included proxies for HLA-DRB1*15:01 and HLA-DRB1*03:01, and
SNPs in moderate linkage disequilibrium (LD) with HLA-A*02:01, HLA-DRB1*04:01 and HLA-DRB1*13:03. We also found a
strong association with rs9277535 in the class II gene HLA-DPB1 (discovery set P~9|10{9, replication set P~7|10{4,
combined P~2|10{10). HLA-DPB1 is located centromeric of the more commonly typed class II genes HLA-DRB1, -DQA1
and -DQB1. It is separated from these genes by a recombination hotspot, and the association is not affected by conditioning
on genotypes at DRB1, DQA1 and DQB1. Hence rs9277535 represents an independent MS-susceptibility locus of genome-
wide significance. It is correlated with the HLA-DPB1*03:01 allele, which has been implicated previously in MS in smaller
studies. Further genotyping in large datasets is required to confirm and resolve this association.
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Introduction
Multiple sclerosis (MS, OMIM 126200) is an autoimmune
disease of the central nervous system which is most prevalent in
young adults of European ancestry. It is hypothesized that immune
dysregulation leads to autoimmune attack on central nervous
system myelin, and that both demyelination and axonal injury play
key roles in disability progession. MS aggregates to some extent in
families, and is clearly triggered by a complex mix of genetic and
environmental factors. In Europeans, the HLA class II haplotype
DRB1*15:01–DQB1*06:02 (DR15) is by far the strongest genetic
risk factor (odds ratio approximately 3). There is evidence of
interaction between this haplotype and environmental risk factors
such as vitamin D [1] and exposure to infant siblings [2]. Recently
genome-wide association (GWA) studies and follow-up studies
have identified many other non-HLA loci associated with MS
susceptibility [3,4,5,6,7,8,9,10,11,12,13,14]. Most of these loci
have been associated with other autoimmune diseases or
encompass genes with known immune functions; the notable
exceptions are associations with two genes involved in axonal
transport [9,13].
There is now also clear evidence of multiple, independent
associations with MS across the major histocompatibility complex
(MHC), as is the case for other autoimmune diseases [15,16].
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13454There have been associations with other alleles of HLA-DRB1
[17,18,19,20,21], independent associations in the class I region
[4,16,22,23,24,25,26,27], and cis [28] and trans [17,29] interac-
tions between alleles of class II genes. The outstanding candidate
genes across the MHC are the highly polymorphic class II and
class I genes which present antigens to CD4+ and CD8+ T cells
respectively, but there are many other compelling candidates in
the HLA complex, which is rich in genes of immune function.
Elucidating causative genes and polymorphisms is harder than
elsewhere in the genome due to the extensive linkage disequilib-
rium (LD) across the region.
To find evidence of independent associations, it is necessary
either to perform stratified analyses or to condition on other
associations. In a recent study, dense SNP genotyping data across
the MHC was explored by conditioning on the predominant
DRB1*15:01 association [16]. In the current study we extend this
approach, conditioning on multiple MS-associated SNPs and
imputed MHC alleles (in addition to DRB1*15:01) to identify
further independent associations and build up multivariate models
of MS-susceptibility. SNPs and alleles in these models were then
validated by genotyping them (or proxies for them) in an
independent replication case-control dataset.
Results
A multivariate SNP model of MS-susceptibility
Our discovery dataset consisted of the genotypes of 1618 MS
cases and 3413 controls of European ancestry at 1927 SNPs across
the MHC and flanking regions, samples which were previously
analysed in a genome-wide association study [6]. We began by
testing all SNPs individually for association with MS using a trend
test. The most strongly associated SNP was rs9271366, a proxy for
the HLA-DRB1*15:01 allele (genotypic squared correlation
r2~0:82 in HapMap CEU data [30], r2~0:96 with DR15 in
two-digit typing of 740 cases from the discovery dataset). In the
second step, we tested all otherSNPs using a trend test, conditioning
on genotype at rs9271366 as a three-level factor. The most
significantly associated SNP was rs2394160 (P~2:0|10{11),
located in an intron of LOC285830 approximately 15 kb centro-
meric of the HLA-F gene in the class I region. This SNP is in strong
LD (r2~0:96) with MS-associated SNPs rs2743951 and rs2523393
reported in previous studies [4,16]. There were six other SNPs with
P-values less than 10{10: five SNPs correlated with rs2394160
(rs2517912, rs1262126, rs2975033, rs6904029, rs4711207, see
Figure 1) and rs2854050 in an intron of NOTCH4.
In the third step, all SNPs were tested conditioning on genotypes at
rs9271366 and rs2394160. The strongest association was with
rs2854050. In subsequent steps we identified four more independent-
ly-associated SNPs (rs3830041, rs3129939, rs2187668, rs9277535),
including a proxy (rs2187668) for the HLA-DRB1*03:01 allele (r2~1
in HapMap CEU) which has been associated with MS previously
[17,18,19,20,29]. No further SNPs were significant after applying a
Bonferroni correction for 1927 tests. Table 1 shows a fitted model
containing additive terms for these seven SNPs.
One might expect the form of this model to be heavily
influenced by the terms included in the model-building procedure
(the 1927 SNPs in the discovery dataset). However when we
repeated the model-building procedure, augmenting the 1927
SNPs with 10,260 haplotype clusters selected using a variable-
length Hidden Markov Model of LD [31,32], the fitted model was
remarkably similar (data not shown). This SNP-plus-haplotype
model included 6 terms: 4 SNPs from the SNP-only model
(rs2394160, rs2854050, rs9271366, rs9277535), and two 2-SNP
haplotypes which each included a SNP from the SNP-only model
(rs2854050, rs2187668). Hence we focused on the SNP-only
model for replication and interpretation.
Figure 1. LD between the seven SNPs in the fitted model (Table 1) and other MHC polymorphisms. The plot shows LD between the 7
model SNPs and other SNPs and classical HLA alleles genotyped in the HapMap CEU population. Points are only plotted for SNP pairs where r2w0:1.
Points are plotted at the genomic positions of the HLA alleles/other SNPs; named points at the top of the plot (r2~1) show the locations of the SNPs
in the model. The various colours are used to distinguish LD with different SNPs in the model (rs2394160 pink, rs2854050 khaki, rs3830041 green,
rs3129939 blue, rs9271366 purple, rs2187668 brown, rs9277535 red). SNPs are shown as small dots and HLA alleles are shown as triangles: refer to
Table 2 for the names of HLA alleles correlated with r2w0:25. Pink stars denote SNPs in LD with rs2394160 that were strongly associated with MS in
the second stage of the model-building (just with adjustment for the DRB1*15:01 proxy SNP rs9271366). The black triangles and crossess show the
locations of some classical HLA genes and other genes respectively that are mentioned in the text. The red bars at the bottom of the graph show
recombination rates averaged over 25kb windows. The vertical dashed lines mark the boundaries of the class I, class III and class II regions of the
MHC.
doi:10.1371/journal.pone.0013454.g001
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genotyping these SNPs, and others across the MHC, in an
independent dataset comprising 2212 cases and 2251 controls. In
the replication data all terms were significant after correcting for
multiple testing (one-sided Pv0:05=9~0:006, Table 1); hence
they were all highly significant in the combined dataset (Pƒ10{8).
In the combined dataset we tested for departures from multi-
plicativity (dominance effects) and interactions with the
DRB1*15:01 proxy rs9271366. There were significant dominance
effects for the DRB1*15:01 and DRB1*03:01 proxy SNPs, and
there was modest evidence of interaction (P~0:002) between
rs2854050 and rs9271366 (Table S1).
Correlations with classical MHC alleles
The seven SNPs in the SNP-only model (Table 1) are in LD
with many other polymorphisms across the MHC. Figure 1 shows
LD (r2w0:1) between the SNPs in the model and other SNPs, as
well as alleles of the classical MHC genes HLA-A, HLA-B, HLA-C,
HLA-DRB1, HLA-DQA1 and HLA-DQB1, in 90 unrelated
individuals from the HapMap CEU population [30]. Table 2
shows classical alleles correlated with r2w0:25.
We investigated the effects of some of these HLA alleles, by
imputing them in the discovery dataset and genotyping proxy
SNPs in the replication dataset. We added imputed allele dosages
and proxy SNPs to the logistic regression model one-by-one, both
with and without the corresponding correlated SNP in the original
model (see Table S2 for imputed dosages and Table S3 for proxy
SNPs).
These analyses provided evidence that associations with the
three most telomeric model SNPs (rs2394160, rs2854050 and
rs3830041) may be driven by LD with MHC alleles that have been
associated with MS previously: HLA-A*02:01 (protective)
[22,23,33], DRB1*04:01 (protective) [20,34] and DRB1*13:03
(susceptibility) [21,35] respectively. In the discovery dataset,
imputed dosages for these three HLA alleles show strong
associations when they are substituted for the relevant SNP
(HLA-A*02:01, P~6:8|10{8; DRB1*04:01, P~6:6|10{5;
DRB1*13:03, P~5:4|10{8, Table S2). In the discovery dataset
rs6904029, which was strongly associated in the second step of the
model building (pink stars in Figure 1), is strongly correlated with
HLA-A*02:01 (r2~0:85). In the replication dataset the association
with rs2394160 completely disappears (P~0:32) after adjustment
for a good proxy for HLA-A*02:01 (rs2523822, r2~0:95, Table
S3). This SNP is highly significant in the model, both with and
without adjustment for rs2394160 (P~4:0|10{15 and
P~1:8|10{7 respectively). After adjustment for rs2394160 in
the replication dataset, there is little evidence of association with
candidate polymorphisms rs2857766 and rs1233334 in the nearby
genes MOG [22,36] and HLA-G [37] (Table S3).
Table 1. Seven SNPs across the MHC independently associated with MS: terms in the fitted logistic regression model.
Discovery dataset: 1618 cases,
3413 controls
Replication dataset: 2212 cases,
2251 controls Combined
3
SNP Position
1
Minor
allele
Major
allele
MAF
cases
MAF
controls P value OR
MAF
cases
MAF
controls P value
2 OR
MAF
cases
MAF
controls P value OR
rs2394160 29,811,241 G A 0.344 0.423 4:0|10{9 0.75 0.359 0.437 1:2|10{9 0.75 0.353 0.429 8:1|10{17 0.76
rs2854050 32,293,583 A G 0.035 0.072 4:7|10{8 0.53 0.039 0.070 6:7|10{5 0.67 0.037 0.071 4:3|10{11 0.60
rs3830041 32,299,317 A G 0.083 0.086 3:8|10{6 1.50 0.074 0.084 0.0014 1.31 0.077 0.085 6:3|10{8 1.41
rs3129939 32,444,744 G A 0.159 0.189 3:7|10{10 0.56 0.166 0.186 2:1|10{5 0.69 0.163 0.188 2:0|10{13 0.62
rs9271366 32,694,832 G A 0.329 0.155 1:3|10{81 3.04 0.339 0.151 7:8|10{90 3.38 0.334 0.153 7:8|10{169 3.19
rs2187668 32,713,862 A G 0.146 0.136 1:1|10{14 2.15 0.148 0.135 1:5|10{11 1.88 0.147 0.136 3:1|10{24 2.01
rs9277535 33,162,839 G A 0.273 0.240 8:6|10{9 1.36 0.265 0.261 6:5|10{4 1.18 0.269 0.249 2:3|10{10 1.27
1SNP positions are from NCBI dbSNP genome build 128 (October 2007).
2One sided P values are used for the replication analysis only.
3Analysis of the combined dataset was adjusted for sample group (discovery/replication).
doi:10.1371/journal.pone.0013454.t001
Table 2. Alleles of the classical MHC genes HLA-A, HLA-C,
HLA-B, HLA-DRB1, HLA-DQA1 and HLA-DQB1 correlated with
SNPs in the fitted logistic regression model (r2§0:25).
SNP in model correlated classical allele r2 in HapMap CEU
rs2394160 HLA-A*02:01 0.49
rs2854050 HLA-C*05:01 0.37
DRB1*04:01 0.37
HLA-B*44:02 0.25
rs3830041 DRB1*13:03 0.49
rs3129939 DRB1*03:01 0.80
DQB1*02:01 0.47
HLA-B*08:01 0.43
HLA-C*07:01 0.39
HLA-A*01:01 0.36
DQA1*05:01 0.27
rs9271366 DRB1*15:01 0.82
DQB1*06:02 0.82
DQA1*01:01 0.68
rs2187668 DRB1*03:01 1.00
DQB1*02:01 0.60
HLA-B*08:01 0.42
HLA-C*07:01 0.38
DQA1*05:01 0.37
HLA-A*01:01 0.36
rs9277535 none
doi:10.1371/journal.pone.0013454.t002
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association with rs3129939 is caused by LD with correlated alleles
of HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQA1 or HLA-DQB1
(Table 2), and rs9277535 shows low correlation with all alleles of
these genes. Table 3 shows an alternative logistic regression model
fitted to the discovery dataset, with the other five SNPs replaced by
imputed dosages for correlated HLA alleles.
Association with a SNP in the gene HLA-DPB1
rs9277535 lies in the 3¿ untranslated region of another class II
gene, HLA-DPB1. All moderately correlated SNPs (r2w0:3,
Figure 1) lie within a 131-kb region (33,155kb–33,286kb) which
also encompasses the genes HLA-DPB2, COL11A2, RXRB,
SLC39A7, HSD17B8, MIR219-1 and RING1. HLA-DPB1 is
centromeric of the class II genes HLA-DRB1, HLA-DQA1 and
HLA-DQB1, and is separated by a region with a high recombi-
nation rate (Figure 1). Consequently, LD is low between
rs9277535 and all DRB1, DQA1 and DQB1 alleles in the HapMap
CEU dataset (r2v0:07). In the discovery dataset, the association
with rs9277535 remains strong after conditioning on imputed
allele dosages at all alleles of DRB1, DQA1 and DQB1
(P~8:1|10{9), and with full conditioning on maximum
likelihood genotypes at DRB1 (P~2:7|10{9); hence the
association is unlikely to be caused by complex interactions
between DRB1 alleles [17,29]. There was no evidence that
rs9277535G exerts different effects in DR15-positive and -negative
individuals (P~0:43 testing for interaction with rs9271366 in the
combined dataset).
The association with rs9277535 is somewhat masked due to
negative confounding by DRB1*15:01, even though LD between
the DRB1 and DPB1 loci is weak. Table S4 shows correlations
between the risk-associated rs9277535 allele and imputed allele
dosages for various classical alleles in the discovery dataset. In
particular, rs9277535G is negatively-correlated with the
DRB1*15:01 allele (r=¿0.09). In an unadjusted analysis of this
SNP in the discovery dataset, the estimated odds ratio for
rs9277535G is 1.19 (P~0:0003). The estimated odds ratio
increases to 1.34 with adjustment for DRB1*15:01 and to 1.36
in the full model (Table 3) after further adjustment for
DRB1*03:01 (negative confounder) and DRB1*04:01 (positive
confounder). In the replication dataset, negative confounding
means that the association with rs9277535 is significant after
adjustment for other terms, even though the overall frequency of
the minor allele is very similar in cases and controls (0.265 and
0.261 respectively).
A recent study showed that there is a highly-conserved vitamin
D response element (VDRE) GGGTGGAGGGGGTTCA imme-
diately upstream of the HLA-DRB1 gene on DRB1*15:01
haplotypes [1]. We searched for Vitamin D Response Elements
(VDREs) associated with the HLA-DPB1*03:01 allele [38], using
the homozygous COX cell line which carries this allele. This in
silico analysis revealed one predicted VDRE. However this
sequence differed from the sequence proximal to HLA-
DRB1*15:01, was not located in the proximal promoter region
of HLA-DPB1*03:01 and was found in all HLA-DPB1 alleles
assessed.
Association with a copy number variant
We observed a copy number variant in the course of genotyping
the HLA-B*44:02 proxy SNP rs2256583CwT in the replication
dataset. This SNP lies between HLA-C and HLA-B in a region
known to contain copy number variants. Plotting areas under the
C- and T-allele peaks revealed three groups of heterozygotes,
which appear to correspond to C:T ratios of 2:1, 1:1 and 1:2
(Figure S1). There were different proportions of cases in the three
groups (Table S5, P~0:008 using Fisher’s exact test). The
heterozygote groupings are not well-correlated with any of the
seven SNPs in the model of Table 1, and these differences remain
almost significant after adjustment for all terms in the SNP model
(P~0:07 using a likelihood ratio test with two degrees of freedom).
There was too much inter-sample variation in peak heights to
detect copy number differences among homozygotes.
Discussion
Using multivariate analysis we identified seven SNPs that were
independently associated with MS, and confirmed all seven
associations in a replication dataset. All associations were highly
significant in the combined dataset (Pƒ6|10{8, Table 1).
Two of these SNPs are proxies for the known associations with
DRB1*15:01 and DRB1*03:01. As in previous analyses [4,16], the
most prominent associations after conditioning on DRB1*15:01
were with SNPs in the vicinity of HLA-A. Hence our data add to
previous, very strong evidence of a functional effect correlated with
rs2394160, rs2743951 [16], rs2523393 [4], rs6904029 and HLA-
A*02:01 [33]. We also found evidence to support previously-
reported associations with the alleles DRB1*04:01 [20,34] and
DRB1*13:03 [21,35].
In MS, strong protective associations have been reported
previously for the class I alleles HLA-C*05:01 [26] and HLA-
B*44:02 [16], which are highly correlated with one another
(r2~0:70 in HapMap CEU data). In an unadjusted analysis, HLA-
B*44:02 is strongly associated with MS in our discovery dataset
(OR 0.67, P~6|10{6), however this association is positively
confounded by the DRB1*15:01 association (r=¿0.05), and by the
(putative) protective effects of HLA-A*02:01 (r~0:20) and
DRB1*04:01 (r~0:30). Hence, HLA-B*44:02 shows little evidence
of association when added to the model in Table 3 (OR=0.92,
P~0:43). Our data provide stronger evidence of an association
with DRB1*04:01 than with HLA-C*05:01 or HLA-B*44:02, but
this evidence is far from definitive. The multivariate analyses
suggest that not all three of these alleles are exerting causative
effects, but further analyses in larger datasets and functional
studies will be required to determine which (if any) are causative.
The most novel association in the model is with the SNP
rs9277535 in the class II gene HLA-DPB1, centromeric of the DR/
DQ region and separated by a recombination hotspot. The DP
region has not been investigated as thoroughly as the DR/DQ
region in genetic association studies. In normal conditions DP
Table 3. Alternative logistic regression model fitted to the
discovery dataset, with five SNPs from the model in Table 1
replaced by imputed dosages for correlated MHC alleles.
Term
in model
Replaced
SNP
Freq
cases
Freq
controls P value OR
HLA-A*02:01 rs2394160 0.200 0.266 3:2|10{8 0.72
DRB1*03:01 rs2187668 0.153 0.143 3:2|10{10 1.84
DRB1*04:01 rs2854050 0.055 0.102 2:1|10{4 0.66
DRB1*13:03 rs3830041 0.021 0.011 1:8|10{7 2.65
DRB1*15:01 rs9271366 0.324 0.153 3:0|10{76 3.05
rs3129939G – 0.159 0.189 1:3|10{5 0.67
rs9277535G – 0.273 0.240 4:8|10{9 1.36
doi:10.1371/journal.pone.0013454.t003
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products [39]; therefore DP typing was difficult with serological
techniques prior to the advent of molecular typing. Associations
with DR and DQ alleles were detected early on for many diseases
including MS [40], so there has been a natural focus on these
genes.
Nevertheless there have been several studies reporting associ-
ations between MS and HLA-DPB1. A SNP rs3135021 in an
intron of HLA-DPB1 was recently associated with MS in African
Americans [41]. The SNP is in LD with some HLA-DRB1 alleles in
African Americans [41], and it is in linkage equilibrium
(r2~0:005) with rs9275535 in the HapMap CEU population.
The DPB1*05:01 allele has been associated with opticospinal MS
in Japan [42] and with MS in Southern Han Chinese [43]. The
DPB1*03:01 allele has been implicated in epitope spreading in MS
[44]. It has also been associated with opticospinal MS in Japan
[45], and with MS in a small Australian study [46] and in Sardinia
[35]. In the Sardinian study, comparing 835 relapsing MS patients
with 592 controls, carriage of the DPB1*03:01 allele was
associated with increased risk of MS (OR 1.30, P~0:03) after
conditioning on an associated microsatellite in the class I region
and on presence or absence of five DRB1–DQB1 risk haplotypes
(three of which include DRB1*15:01, DRB1*03:01 and
DRB1*13:03). We tested for presence/absence of the
DPB1*03:01 allele in 422 Australian MS cases using a combina-
tion of sequence specific priming and sequence based typing, and
found a correlation with rs9277535 (r2~0:35, Table S6): all but
two individuals carrying the DPB1*03:01 allele also carry the
rs9277535G allele.
Mechanisms other than peptide affinities for HLA molecules
may be underpinning some of these associations. The HLA
complex has a particularly high density of copy number variants,
and these represent one possible source of functional variation. In
the course of replication genotyping we identified a copy number
variant between the genes HLA-B and HLA-C which showed some
evidence of independent association with MS susceptibility.
Disease-associated variants may also be acting via effects on
gene expression [47]. A recent study suggests that a vitamin D
response element (VDRE) upstream of HLA-DRB1 plays an
important role in expression of this gene [1]. VDREs are bound by
the vitamin D receptor (VDR) which acts as a ligand activated
transcription factor, and the VDRE upstream of HLA-DRB1 is
highly conserved on DRB1*15:01 haplotypes. It was found that the
DRB1*15:01 haplotype binds the VDR more efficiently than other
haplotypes, in particular the 98% of DRB1*04, DRB1*07 and
DRB1*09 haplotypes where this sequence differs at two nucleo-
tides (GGGTGGAGAGGGGTCA) [1]. We observed that the
homozygous COX and QBL lymphoblastoid cell lines, which both
carry the risk-associated HLA-DRB1*03:01 allele, have an identical
proximal VDRE to that occurring on the DRB1*15:01 haplotype.
This is noteworthy given that the amino acid sequences of
DRB1*15:01 and DRB1*03:01 are not particularly similar
compared to other DRB1 alleles.
We also searched for VDREs associated with the HLA-
DPB1*0301 allele, but did not find convincing evidence of an
active response element. One of the genes in the region of LD
around HLA-DPB1 is retinoid X receptor beta (RXRB). This gene
encodes a receptor which forms a dimer with VDR and increases
its DNA binding and transcriptional function [48].
In summary, we have detected a highly significant association
with MS in the vicinity of the HLA-DPB1 gene that is independent
of other MS associations in the HLA complex, confirming
suggestive reports from previous smaller studies. Our data indicate
that DPB1*03:01 may be the causative HLA allele underpinning
this association, however positive replication studies followed by
fine mapping will be required to confirm and resolve this
association in other populations. Our study also highlights the
utility of multivariate analysis to disentangle HLA associations for
autoimmune diseases, such as MS, which have multiple genetic
risk factors in the HLA complex. This approach will be useful
more generally at other loci and for other diseases, as more clusters
of associations are identified [14,49].
Materials and Methods
Approval for this research was granted by the Melbourne
Health Human Research Ethics Committee and other institutional
ethics committees. Written consent was given by the patients for
their information to be stored in the study database and used for
research.
To identify SNPs across the MHC independently associated
with MS, we analysed genotype data assembled for a GWA study
[6]. After data cleaning followed by principal components analysis
to remove population outliers [6], this dataset comprised 1618 MS
cases of European ancestry from Australia and New Zealand, and
3413 European-ancestry controls from Australia, the UK and US.
All samples were genotyped with Illumina arrays.
The cleaned discovery dataset included genotypes at 1927 SNPs
across the MHC and flanking regions (chr6: 24–36 Mb, NCBI
dbSNP genome build 128). We used a stepwise logistic regression
procedure to identify SNPs independently associated with disease
status, building a model with increasing numbers of independently
associated SNPs. At each step we used a trend test to identify the
most significantly associated SNP after conditioning on SNPs
already in the model, then added this SNP to the model.
Conditioning on SNPs already in the model was performed by
coding their genotypes as three-level factors. The procedure was
repeated until no further SNPs were significant after applying a
Bonferroni correction to correct for 1927 tests. In the final model
fitted to the discovery dataset (Table 1), all SNPs in the model were
coded as quantitative variables (trend test) rather than factors. The
final model was also fitted to the discovery dataset with adjustment
for position along the first three eigenvectors of the final principal
components analysis [6]; with this additional adjustment no
coefficients of SNPs changed by more than 7% and all remained
significant at Pv2|10{6 (full data not shown).
Twenty-five SNPs across the HLA region were genotyped in an
independent replication dataset of MS cases and controls from
Australia and New Zealand described previously [6], using the
Sequenom MassARRAY system and iPlex Gold chemistry. These
SNPs included the seven SNPs in the fitted model (Table 1),
candidate polymorphisms in the genes MOG and HLA-G, proxies
for several classical MHC alleles, and backups in case of assay
failure. After excluding 147 samples with call rates less than 90%,
the filtered replication dataset comprised 2212 cases and 2251
controls. In this filtered dataset call rates were above 99.7% for all
25 SNPs.
We fitted the same 7-SNP logistic regression model to the
replication dataset and to the combined dataset. Two-sided P
values were used throughout except in the analysis of the
replication dataset. Analysis of the combined dataset was adjusted
for sample group (discovery/replication). In the replication dataset
we also fitted a 7-SNP model using an alternative proxy rs3135388
for HLA-DRB1*15:01 [30]; in this alternative model the
magnitudes of the coefficients of rs2854050 and rs3830041
decreased by 32% and 13% respectively but remained significant
(Pv0:004), and no other coefficients changed by more than 6%
(full data not shown).
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discovery dataset we downloaded phased data for individuals from
the HapMap CEU population (Utah residents with ancestry from
northern and western Europe), including classical HLA typing
data for the genes HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-
DQA1 and HLA-DQB1 (http://www.inflammgen.org) [30]. In the
discovery dataset we imputed genotypes at classical HLA alleles
using the software BEAGLE (http://www.stat.auckland.ac.nz/
bbrowning/beagle/beagle.html) [50]. Imputation was done by
dividing the samples randomly into batches of 50, and running
each batch with the phased HapMap CEU data. The default
settings in BEAGLE were changed to allow consideration of long
haplotypes spanning the entire region, which has proven beneficial
for imputation of HLA alleles [51]. For each classical allele we
calculated posterior allele dosage, which is twice the posterior
probability of carrying two copies of the allele plus the posterior
probability of carrying exactly one copy of the allele. These
posterior allele dosages were used as predictive variables in logistic
regression models (Table 3, Table S2).
MHC sequences for HLA-homozygous cell lines were down-
loaded from the website of the MHC Haplotype project (https://
www.sanger.ac.uk/HGP/Chr6/MHC/). We searched for
VDREs associated with the HLA-DPB1*03:01 allele using the
sequence for this allele (carried by the homozygous cell line COX).
The sequence was scanned for VDREs using JASPAR (http://
jaspar.genereg.net) [38] with a profile threshold of 80%.
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Table S1 The 7-SNP model in the combined dataset, with two
significant dominance effects and one significant SNP-SNP
interaction added
Found at: doi:10.1371/journal.pone.0013454.s001 (0.02 MB
PDF)
Table S2 The effects of adding correlated MHC alleles to the
fitted model in the discovery dataset (Table 1), both with and
without the correlated SNP. For these analyses imputed MHC
allele dosages were calculated using the software BEAGLE (50).
Found at: doi:10.1371/journal.pone.0013454.s002 (0.03 MB
PDF)
Table S3 The effects of adding other SNPs genotyped in the
replication dataset to the fitted model (Table 1), both with and
without the correlated SNP from the model.
Found at: doi:10.1371/journal.pone.0013454.s003 (0.03 MB
PDF)
Table S4 Correlations between various SNPs and imputed
classical alleles in the discovery dataset
Found at: doi:10.1371/journal.pone.0013454.s004 (0.01 MB
PDF)
Table S5 A copy number variant at SNP rs2256583: numbers of
heterozygous cases and controls with various C:T allele ratios in
the replication dataset
Found at: doi:10.1371/journal.pone.0013454.s005 (0.01 MB
PDF)
Table S6 Correlation between HLA-DPB1*0301 and
rs9277535 in 422 MS cases
Found at: doi:10.1371/journal.pone.0013454.s006 (0.01 MB
PDF)
Figure S1 A copy number variant at SNP rs2256583. A plot of
area under the C- allele peak (y-axis) versus area under the T-allele
peak (x-axis) for heterozygotes, showing three groups of individuals
with C:T ratios of 1:2 (red), 1:1 (green) and 2:1 (blue).
Found at: doi:10.1371/journal.pone.0013454.s007 (0.16 MB
PDF)
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